RELEASE DETAILS

WALTHAM, Mass.--(BUSINESS WIRE)--May 8, 2018-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that Mark Iwicki, Chairman and Chief Executive Officer, will provide a corporate overview at the Bank of America Merrill Lynch 2018 Health Care Conference and the Jefferies 2018 Global Healthcare Conference. Details of the presentations are as follows:

Bank of America Merrill Lynch 2018 Health Care Conference
Date: Tuesday, May 15, 2018
Time: 11:35 AM PT
Location: Las Vegas, NV

Jefferies 2018 Global Healthcare Conference
Date: Tuesday, June 5, 2018
Time: 9:00 AM ET
Location: New York, NY

To access a live webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180508005459/en/

Source: Kala Pharmaceuticals, Inc.

Investor and Media Contact:
MacDougall Biomedical Communications
Cammy Duong, 781-591-3443
cduong@macbiocom.com